Cost-utility analysis of osimertinib for adjuvant treatment of epidermal grouth factor receptor mutation-positive non-small cell lung cancer

LIU Jia, HE Xiaoning

PDF(4263 KB)
主办：上海医药工业研究院
　　　中国药学会
ISSN 1672-9188   CN 31-1939/R   SLYHAA
World Clinical Drug
PDF(4263 KB)
World Clinical Drug ›› 2022, Vol. 43 ›› Issue (06) : 736-745. DOI: 10.13683/j.wph.2022.06.015
Article

Cost-utility analysis of osimertinib for adjuvant treatment of epidermal grouth factor receptor mutation-positive non-small cell lung cancer

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2022, 43(06): 736-745 https://doi.org/10.13683/j.wph.2022.06.015

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(4263 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉